3 - Ultra high quality proteins


Value proposition / USP:

Due to patented protein preparation methods, our human 20S proteasomes have unmatched characteristics:

  • 10-fold increase in specific activity, compared to what has been published to-date
  • Regularly crystallize and diffract to below 2.2A, best resolution 1.8A


Success story (example):

Previous inhibitors of the 20S proteasome were lacking sufficient resolution of electron density in the proteasome's active site to unequivocally model the inhibited state in atomic detail. Our new crystal structures of the 20S proteasome with achieved resolutions of 1.8 to 2.2A provided this insight and allowed to propose a new chemical mechanism for the inhibition of the 20S proteasome.


Business model:

Sell proteins


Datasheet Human 20S Proteasome - ProteoPlex
20170117 data sheet ProteoPlex 20S Prote[...]
PDF-Dokument [72.2 KB]



Extend portfolio (same USP as above):

  • Human 26S/30S proteasome
  • Human immunoproteasome
  • Fatty acid synthase
  • Pre-mix of crystallization and stabilization conditions


Suggested further reading:

Schrader, J.; Henneberg, F.; Mata, R.; Tittmann, K.; Schneider, T.; Stark, H.; Bourenkov, G.; Chari, A.: The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design. Science Research Report, Vol. 353, Issue 6299, pp. 594-598 (2016)


Download: http://science.sciencemag.org/content/353/6299/594



Exclusive delivery contract with Max-Planck


Potential collaborators:

  • CROs that do complex structures for pharmaceutical companies
  • Pharmaceutical companies that work with respective targets


Our structures in the EMBD:

Joint press release with NovAliX, 27th March 2018

"NovAliX enters into cooperation agreement with ProteoPlex"

Press release EMBL,

4th Aug 2016:

"Every atom counts"

EMBL Science,

8th Aug 2016:

"Blocking the cell's waste disposal unit"